熱點掃描 |
uSMART盈立智投3月23日消息，截止發稿，港股三大指數齊漲跌互現，恆生指數上漲1.89%，報22300.13點，成交額861.71億；國企指數上漲2.23%，報7707.46點，成交額372.99億；紅籌指數下跌0.42%，報3996.53點，成交額24.42億。
短視頻概念股全線上漲，微盟集團漲超19%，中國有贊漲超11%，映客漲超8%，快手、輝煌明天漲超7%；
醫藥外包概念上揚，藥明生物、藥明康德漲超9%，康龍化成漲超7%，泰格醫藥漲超6%；
汽車股拉昇，蔚來漲超9%，小鵬汽車漲超7%，比亞迪股份漲超6%，吉利汽車漲超5%；
在線教育股走高，新東方漲近9%，思考樂教育漲超6%，新東方在線漲超4%。
熱門股
加科思漲8.64%，報7.29港元。加科思藥業於3月22日公佈2021年全年業績，作爲一家臨牀階段的生物科技公司，加科思通過一項對外授權交易，實現營收1.53億元。研發投入4.21億元，同比增長83%。“加科思研發投入在2020年增長66%的基礎上，2021年繼續增長83%，2022年將繼續增加研發投入。加科思的管線圍繞六大腫瘤信號通路(RAS、MYC、RB、I/O、腫瘤代謝、P53)佈局，有多個處於臨牀前階段的項目有望以全球前三的速度在未來一兩年內遞交新藥臨牀試驗申請。屆時，加科思將進一步兌現'核心項目全球前三'的戰略目標。"公司董事長兼CEO王印祥博士表示；
亞盛醫藥漲7.4%，報18港元，該公司3月22日公佈，其在研原創新藥MDM2-p53抑制劑APG-115(alrizomadlin)，獲得美國食品和藥監局(FDA)授予的兒童罕見病資格認證(Rare Pediatric Disease，RPD)，用於治療神經母細胞瘤；
平安好醫生(1833.HK)漲8.33%，報22.8港元，根據聯交所最新權益披露資料顯示，2022年3月16日，平安好醫生獲JPMorgan Chase & Co.以每股均價15.3206港元增持好倉1021.54萬股，涉資約1.57億港元。增持後，JPMorgan Chase & Co.最新持好倉數目爲5770.79萬股，持好倉比例由4.2%上升至5.1%；
東嶽集團漲16.05%，報11.26港元發改委發佈《氫能產業發展中長期規劃（2021-2035 年）》提出，加快推進質子交換膜燃料電池技術創新，開發關鍵材料，提高 主要性能指標和批量化生產能力，持續提升燃料電池可靠性、穩定性、耐久性。支持新型燃料電池等技術發展。着力推進核心零部件以及關鍵裝備研發製造。加快提高可再生能源制氫轉化效率和單臺 裝置制氫規模，突破氫能基礎設施環節關鍵核心技術。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
